GT Biopharma, Inc. (GTBP)

GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Depreciation & Amortization	-	-	-	-	-	0
Other Amortization	-	-	-	-	0.32	0.51
Loss (Gain) From Sale of Assets	-	-	-	-	-	20.49
Asset Writedown & Restructuring Costs	-	-	-	-	0.06	4.6
Loss (Gain) From Sale of Investments	-0.02	-0.05	0.03	0.03	-	-
Stock-Based Compensation	1.48	2.2	7.65	33.93	0.27	5.31
Other Operating Activities	-2.43	-5.23	-0.02	0.51	17.98	-
Change in Accounts Payable	0.64	1.96	-2.03	7.08	-0.84	3.15
Change in Other Net Operating Assets	-0.15	-0.14	0.04	0.86	3.24	0.92
Operating Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.66
Sale of Property, Plant & Equipment	-	-	-	-	-	0.2
Investment in Securities	10.01	-2.01	12.15	-23.04	-	-
Investing Cash Flow	10.01	-2.01	12.15	-23.04	-	0.2
Short-Term Debt Issued	-	-	-	1.21	12.53	3.53
Total Debt Issued	-	-	-	1.21	12.53	3.53
Short-Term Debt Repaid	-	-	-	-	-	-0.1
Total Debt Repaid	-	-	-	-	-	-0.1
Net Debt Issued (Repaid)	-	-	-	1.21	12.53	3.43
Issuance of Common Stock	-	6.27	-	41.11	-	-
Repurchase of Common Stock	-	-	-0.22	-	-	-
Financing Cash Flow	-	6.27	-0.22	42.32	12.53	3.43
Net Cash Flow	-0.1	-4.59	-3.3	3.67	5.27	-0.03
Free Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.66
Free Cash Flow Per Share	-7.11	-6.57	-14.33	-16.63	-49.68	-32.44
Cash Interest Paid	0.21	0.21	-	-	-	-
Levered Free Cash Flow	-6.08	-4.7	-10.91	-0.82	-3.42	0.23
Unlevered Free Cash Flow	-6.08	-4.57	-10.9	-0.38	-1.66	1.06
Change in Net Working Capital	-0.57	-1.72	5.26	-1.64	-2.29	-2.91

Source: S&P Capital IQ. Standard template.